Kioxia Sampling UFS Ver. 4.1 Embedded Flash Memory Devices
Business Wire India
Kioxia Corporation, a world leader in memory solutions, today announced that it has begun sampling new Universal Flash Storage(2) (UFS) Ver. 4.1 embedded memory devices, reinforcing its leadership in high-performance storage. Engineered to meet the demands of next-generation mobile applications, including advanced smartphones with on-device AI, the new devices offer improved performance with greater power efficiency(3), in a small BGA package.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250707306499/en/
Kioxia: UFS Ver. 4.1 Embedded Flash Memory Devices for Next-generation Mobile Applications
UFS Ver. 4.1 devices from Kioxia integrate the company's innovative BiCS FLASH™ 3D flash memory and a controller in a JEDEC-standard package. These new UFS devices are built with Kioxia's 8th generation BiCS FLASH™ 3D flash memory(1). This generation introduces CBA (CMOS directly Bonded to Array) technology—an architectural innovation that marks a step-change in flash memory design. By directly bonding the CMOS circuitry to the memory array, CBA technology enables major gains in power efficiency, performance and density.
With a blend of speed and low power use, Kioxia's UFS Ver. 4.1 devices are built to enhance user experiences—enabling faster downloads and smoother app performance.
Key Features include: Available in capacities of 256 gigabytes (GB), 512 GB and 1 terabyte (TB)
Performance improvement over previous generation (3) : Random writes: 512 GB / 1 TB approx. +30% Random reads: 512 GB approx. +45%, 1 TB approx. +35%
: Power efficiency improvement over previous generation (3) : Reads: 512 GB / 1 TB approx. +15% improvement Writes: 512 GB / 1 TB approx. +20% improvement
: Host Initiated Defragmentation enables delayed garbage collection for uninterrupted fast performance during critical times
WriteBooster buffer resizing provides better flexibility for optimal performance
Support of the UFS Ver. 4.1 standard
Reduced package height for the 1 TB model compared to the prior generation (4)
Uses Kioxia's 8th generation BiCS FLASH™ 3D flash memory(1)
Related Link: Kioxia's UFS 4.1 Product Page
https://www.kioxia.com/en-jp/business/memory/mlc-nand/ufs4.html
Notes: (1) 512 GB / 1 TB models only. (2) Universal Flash Storage (UFS) is a product category for a class of embedded memory products built to the JEDEC UFS standard specification. Due to its serial interface, UFS supports full duplexing, which enables both concurrent reading and writing between the host processor and UFS device. (3) Compared to the previous generation 512 GB device 'THGJFMT2E46BATV' and 1 TB device 'THGJFMT3E86BATZ' respectively (512 GB / 1 TB models only).
(4) The previous generation 1 TB device 'THGJFMT3E86BATZ'.
*In every mention of a Kioxia product: Product density is identified based on the density of memory chip(s) within the Product, not the amount of memory capacity available for data storage by the end user. Consumer-usable capacity will be less due to overhead data areas, formatting, bad blocks, and other constraints, and may also vary based on the host device and application. For details, please refer to applicable product specifications. The definition of 1 KB = 2^10 bytes = 1,024 bytes. The definition of 1 Gb = 2^30 bits = 1,073,741,824 bits. The definition of 1 GB = 2^30 bytes = 1,073,741,824 bytes. 1 Tb = 2^40 bits = 1,099,511,627,776 bits. 1 TB = 2^40 bytes = 1,099,511,627,776 bytes.
*Read and write speeds are the best values obtained in a specific test environment at Kioxia Corporation and Kioxia Corporation warrants neither read nor write speeds in individual devices. Read and write speed may vary depending on device used and file size read or written.
*Company names, product names and service names may be trademarks of third-party companies.
About Kioxia
Kioxia is a world leader in memory solutions, dedicated to the development, production and sale of flash memory and solid-state drives (SSDs). In April 2017, its predecessor Toshiba Memory was spun off from Toshiba Corporation, the company that invented NAND flash memory in 1987. Kioxia is committed to uplifting the world with 'memory' by offering products, services and systems that create choice for customers and memory-based value for society. Kioxia's innovative 3D flash memory technology, BiCS FLASH™, is shaping the future of storage in high-density applications, including advanced smartphones, PCs, SSDs, automotive systems, data centers and generative AI systems.
Customer Inquiries: Kioxia Corporation Global Sales Offices
https://www.kioxia.com/en-jp/business/buy/global-sales.html
*Information in this document, including product prices and specifications, content of services and contact information, is correct on the date of the announcement but is subject to change without prior notice.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250707306499/en/
Disclaimer: The above press release comes to you under an arrangement with Business Wire India. Business Upturn take no editorial responsibility for the same.
Ahmedabad Plane Crash
Business Wire India, established in 2002, India's premier media distribution company ensures guaranteed media coverage through its network of 30+ cities and top news agencies.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Upturn
8 hours ago
- Business Upturn
76% of Indian Healthcare Professionals Are Optimistic That AI Can Improve Patient Outcomes: Philips Future Health Index 2025
Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology and innovation, announced the India findings of its 10th annual Future Health Index (FHI) 2025 report. The findings point to a growing majority of healthcare professionals viewing artificial intelligence (AI) as a vital tool in the delivery of better patient care even as India faces rising healthcare demand and persistent workforce shortages. Business Wire India Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology and innovation, announced the India findings of its 10th annual Future Health Index (FHI) 2025 report. The findings point to a growing majority of healthcare professionals viewing artificial intelligence (AI) as a vital tool in the delivery of better patient care even as India faces rising healthcare demand and persistent workforce shortages. According to the India findings of the Philips Future Health Index (FHI) 2025, 76% of Indian healthcare professionals (HCPs) are optimistic that AI can help improve patient outcomes – a clear sign of the increasing trust in digital transformation as a driver of quality healthcare. This year, the Future Health Index, one of the world's largest recurring healthcare research initiatives, captures insights from over 1,900 healthcare professionals and 16,000 patients across 16 countries. The India report draws insights from healthcare professionals across public and private sectors. The data highlights how AI is increasingly being perceived not merely as a tool for efficiency, but also to expand access, improve clinical quality, and reduce professional fatigue. Commenting on the India findings, Bharath Sesha, Managing Director, Philips Indian Subcontinent, said, ' India stands at a pivotal moment in healthcare transformation. What we're seeing today is a growing trust in AI not just as a tool for efficiency but as a catalyst for better clinical outcomes, broader access, and more empowered healthcare professionals. The findings from this year's Future Health Index India report reaffirm what we've long believed – that technology, when applied with purpose, can bridge the gap between capability and capacity. It is encouraging to see patients' readiness to embrace this transformation, and belief from over 80% Indian Healthcare professionals that AI could save lives by enabling early interventions. This trust is essential to scale up the use of AI and other relevant technology interventions to provide better care for more people." Key findings from FHI 2025 India report: Empowering the Healthcare Workforce With 75% of respondents saying AI-supported training is helpful for less experienced staff, especially in underserved areas, the opportunity to build a future-ready workforce is clear. Indian healthcare professionals view AI as a catalyst for clinical learning, skill-building, and co-developing solutions tailored to real-world healthcare challenges. 78% believe AI can ensure greater consistency in patient examinations, which could help address the issue of standardising care. 87% believe AI can improve access to clinical research 72% say AI can enable accurate and timely interventions While over half (56%) of HCPS in India are already contributing to AI development within their organizations, only four in ten feel these tools align with their day-to-day clinical needs, underscoring the need for more inclusive, hands-on collaboration in shaping technology that delivers meaningful impact. Optimising Care Every Step of the Way From triage to time-saving automation,76% of Indian healthcare professionals believe AI can direct patients to the appropriate care setting, enhancing access while enhancing limited healthcare resources. 78% believe AI can help reduce patients' wait times 60% say it can increase face-to-face time with patients 80% see AI as a way to automate repetitive tasks, which will help reduce administrative burden 65% believe AI can shorten procedure times Caution meets optimism: Addressing key limitations While the outlook is optimistic, several critical gaps must be bridged to realise the full potential of AI in Indian healthcare: 45% of HCPs want clear guidelines on AI usage and its limitations. 44% seek greater clarity on legal liability when using AI in patient care. 31% are looking for reassurance about data security. In addition, 67% express concern that data bias in AI tools could widen healthcare disparities. As the nation advances on its digital health journey, with the right partnerships and policies in place, India is well-positioned to lead the way in demonstrating how technology and trust can together shape a healthier, more equitable future. For more information, download the full FHI 2025 India Report here. Here's the news Center link: Disclaimer: The above press release comes to you under an arrangement with Business Wire India. Business Upturn take no editorial responsibility for the same. Ahmedabad Plane Crash
Business Upturn
a day ago
- Business Upturn
Novotech Report: How In-Vivo CAR-T May Reshape Cell Therapy Economics
Business Wire India With in-vivo CAR-T therapies gaining global momentum, a new whitepaper from Novotech, a leading global full-service clinical Contract Research Organization (CRO) and scientific advisory company, offers insight into this next frontier of immunotherapy. In-Vivo CAR Therapies – Global Research and Development Landscape (2025) report explores the accelerating innovation in in-vivo CAR-T (Chimeric Antigen Receptor) technologies and their potential to reshape treatment across oncology, autoimmune diseases, and other complex indications. This press release features multimedia. View the full release here: In Vivo Car T Infographic from Novotech Traditional ex-vivo CAR-T therapies require extracting a patient's T cells, engineering them in specialized labs, and reinfusing them, a process that is time-intensive, expensive, and logistically complex. These barriers have significantly restricted patient access. In contrast, in-vivo CAR-T therapies aim to overcome these challenges by engineering T cells directly within the patient's body using delivery technologies such as viral vectors, lipid nanoparticles (LNPs), and advanced mRNA platforms. The result: faster, more scalable, and potentially off-the-shelf treatments that can expand access, reduce costs, and streamline the patient experience. In-vivo CAR-T platforms are now being explored not only for hematologic malignancies, but also for solid tumors and autoimmune diseases—areas where traditional CAR-T approaches have faced limitations. Emerging delivery innovations and new combination strategies are driving this expansion. As a result, in-vivo CAR-T therapies are positioned to reshape clinical practice, expanding their applicability across oncology, autoimmune diseases, and beyond. The report provides key insights for sponsors, investors, and researchers into one of the most transformative areas of next-generation cell therapy. It includes: The technological evolution of CAR platforms and delivery systems. The expanding global pipeline of in-vivo CAR assets and clinical programs. Innovations in lipid nanoparticle (LNP) and viral vector delivery strategies. Commercial and regulatory considerations shaping future adoption. Opportunities for in-vivo CAR approaches beyond oncology, including autoimmune diseases and fibrosis. Novotech has an established track record of supporting in-vivo CAR-T programs globally, including conducting the world's first in-vivo CAR clinical trial, highlighting its leadership and deep expertise in advanced therapeutics, including gene and cell therapies. The company has also conducted more than 100 ATMP studies, spanning gene therapies, gene-modified cell therapies, and mRNA products. Novotech is also actively partnering with biotech sponsors advancing in-vivo CAR pipelines. Download the full whitepaper to explore the key trends and opportunities driving the future of in-vivo CAR-T therapy. About Novotech Novotech is a globally recognized full-service clinical research organization (CRO) and scientific advisory company trusted by biotech and small- to mid-sized pharmaceutical companies to guide drug development at every phase. With a global footprint that includes 30+ offices across the Asia-Pacific region, North America, and Europe and partnerships with 5,000+ trial sites, Novotech provides clients an accelerated path to bring life-changing therapies to market by providing access to key clinical trial destinations and diverse patient populations. Through its client-centric service model, Novotech seamlessly integrates people, processes, and technologies to deliver customized solutions that accelerate the path to market for life-changing therapies. By adopting a true partnership approach, Novotech shares a steadfast commitment to client success, empowering innovation, and advancing healthcare worldwide. Recipient of numerous industry accolades, including the Frost & Sullivan CRO Company of the Year award for 19 consecutive years, Novotech is recognized for its excellence in clinical trial execution and innovation. Its deep therapeutic and regulatory expertise, combined with local market insights, ensures streamlined clinical trials, optimized data analytics, and accelerated patient recruitment strategies. Together with clients, Novotech transforms scientific advancements into therapies that improve global health outcomes, embodying a mission of driving innovation and delivering impactful results. For more information or to speak to an expert team member visit View source version on Disclaimer: The above press release comes to you under an arrangement with Business Wire India. Business Upturn take no editorial responsibility for the same. Ahmedabad Plane Crash
Business Upturn
a day ago
- Business Upturn
Kinaxis Inc. to Host Second Quarter 2025 Financial Results Conference Call on August 7, 2025
By Business Wire India Published on July 17, 2025, 16:59 IST Business Wire India Kinaxis® Inc. (TSX:KXS), a global leader in end-to-end supply chain orchestration, today announced that it has scheduled its conference call to discuss the financial results for its second quarter ended June 30, 2025. The call will be hosted on Thursday, August 7 at 8:30 a.m. Eastern Time by Bob Courteau, interim chief executive officer and chair, and Blaine Fitzgerald, chief financial officer, followed by a question and answer period. The Company will report its financial results for the second quarter after the close of markets on Wednesday, August 6, 2025. CONFERENCE CALL DETAILS DATE: Thursday, August 7, 2025 TIME: 8:30 a.m. Eastern Time CALL REGISTRATION: WEBCAST: (available for three months) Advance call registration Participants must register in advance for the live call. After registering, instructions on how to join the call will automatically be emailed, including dial-in information as well as a unique pincode. At the time of the call, registered participants will dial in using the numbers from the confirmation email, and upon entering their unique pincode, will be entered directly into the conference. It is recommended that you register for the call at least 15 minutes prior to the start time. About Kinaxis Kinaxis is a global leader in modern supply chain orchestration, powering complex global supply chains and supporting the people who manage them, in service of humanity. Our powerful, AI-infused supply chain orchestration platform, Maestro™, combines proprietary technologies and techniques that provide full transparency and agility across the entire supply chain — from multi-year strategic planning to last-mile delivery. We are trusted by renowned global brands to provide the agility and predictability needed to navigate today's volatility and disruption. For more news and information, please visit or follow us on LinkedIn. SOURCE: Kinaxis Inc. View source version on Disclaimer: The above press release comes to you under an arrangement with Business Wire India. Business Upturn take no editorial responsibility for the same. Ahmedabad Plane Crash Business Wire India, established in 2002, India's premier media distribution company ensures guaranteed media coverage through its network of 30+ cities and top news agencies.
